Influenza A virus H5N1 vaccine - Medicago

Drug Profile

Influenza A virus H5N1 vaccine - Medicago

Alternative Names: H5N1 avian influenza virus-like particle (VLP) vaccine - Medicago; H5N1 VLP vaccine - Medicago; One-dose H5N1 VLP vaccine - Medicago; Pandemic flu vaccine - Medicago; Plant-derived influenza vaccines - Medicago; Plant-made H5 VLP influenza vaccine - Medicago

Latest Information Update: 03 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medicago
  • Developer Infectious Disease Research Institute; Medicago
  • Class Influenza A virus H5N1 vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza A virus H5N1 subtype

Most Recent Events

  • 01 Jan 2014 Infectious Disease Research Institute completes a phase I trial for Influenza-A virus H5N1 subtype (prevention, in volunteers) in USA (SC or Intradermal) (NCT01657929)
  • 18 Nov 2013 Medicago completes enrolment in its phase II trial for Influenza-A virus H5N1 subtype in Canada (NCT01991561)
  • 18 Sep 2013 Medicago has been acquired by Mitsubishi Tanabe Pharma Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top